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Background: The poor response to chemotherapy and the brief response to vemurafenib in metastatic melanoma
patients, make the identification of new therapeutic approaches an urgent need. Interestingly the increased expression
and activity of the Aurora kinase B during melanoma progression suggests it as a promising therapeutic target.
Methods: The efficacy of the Aurora B kinase inhibitor barasertib-HQPA was evaluated in BRAF mutated cells, sensitive
and made resistant to vemurafenib after chronic exposure to the drug, and in BRAF wild type cells. The drug effectiveness
has been evaluated as cell growth inhibition, cell cycle progression and cell migration. In addition, cellular effectors of
drug resistance and response were investigated.
Results: The characterization of the effectors responsible for the resistance to vemurafenib evidenced the increased
expression of MITF or the activation of Erk1/2 and p-38 kinases in the newly established cell lines with a phenotype
resistant to vemurafenib. The sensitivity of cells to barasertib-HQPA was irrespective of BRAF mutational status.
Barasertib-HQPA induced the mitotic catastrophe, ultimately causing apoptosis and necrosis of cells, inhibited cell
migration and strongly affected the glycolytic metabolism of cells inducing the release of lactate. In association i) with
vemurafenib the gain in effectiveness was found only in BRAF(V600K) cells while ii) with nab-paclitaxel, the combination
was more effective than each drug alone in all cells.
Conclusions: These findings suggest barasertib as a new therapeutic agent and as enhancer of chemotherapy in
metastatic melanoma treatment.
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Metastatic melanoma (MM) is amongst the most resistant
solid tumors to chemotherapy, radiotherapy, and prior in-
vestigational agents. Prior to 2011, only few chemothera-
peutic agents in common use had achieved regulatory
approval for treatment of MM and none resulted in sig-
nificantly improved survival. Robust advances in our un-
derstanding of the molecular biology of melanoma and on
the complex role of host immunity have opened the field
of melanoma therapy to molecularly targeted agents and* Correspondence: a.azzariti@oncologico.bari.it
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spectively. Emerging data from recently completed clinical
trials and preliminary data from ongoing studies testing
novel targeted agents suggest BRAF inhibitors vemurafe-
nib and dabrafenib in patients carrying V600E mutation of
BRAF gene and ipilimumab, a human monoclonal anti-
body that blocks the activity of CTLA-4 antigen inducing
a modulation of T-cell activity as new therapeutic options
[1]. Patients treated with a BRAF inhibitor had a clinically
significant prolongation of survival over 13-16 months as
a first line therapy [2,3] and rapid tumour regression; how-
ever, the majority of them acquires resistance to therapy
and relapses very rapidly [4]. So far, several mechanisms of
resistance involving different molecular pathways have. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the proliferation and survival pathways, the amplification
of MITF and/or CDK-2 and so on and numerous are the
attempts that are being explored to overcome the resist-
ance [5]. One of recent approach followed by most scien-
tists is to block the MAPK pathway, which is activated in
the establishment of resistance to BRAF inhibitors. This
therapeutic approach involves the use of MEK inhibitors,
but unfortunately the published results are not as promis-
ing as hoped by scientific audience [6]. Very promising re-
sults are being obtained with the combination therapy
anti-BRAF plus anti-MEK [7]. Frequent is the question
whether there is a role for chemotherapy in MM [8].
Recently, new chemotherapeutic molecules have been
investigated and some of them demonstrated high activity
in MM. Over all is Abraxane, a solvent-free albumin-
stabilized nanoparticle formulation of paclitaxel which has
been investigated in different cancers reporting very
positive results [9]. The preliminary results of a large,
open-label multicenter phase III trial, recently concluded
and comparing abraxane vs. dacarbazine in previously-
untreated patients with MM, have confirmed the positive
results of previous phase II studies with clinically mean-
ingful benefit in both BRAF mutated and wild type
patients with acceptable toxicity, hence it should be con-
sidered among the treatment options for MM patients
treatment [10-12]. Although in preclinical investigations,
several Aurora kinases inhibitors, such as MLN8054,
PHA-739358, VE-465, ZM447439, SNS-314 and JNJ-
7706621, have been utilized in preclinical studies on mel-
anoma models, demonstrating to inhibit cell proliferation,
to induce apoptosis, and to inhibit cell migration in mel-
anoma as respect to melanocytes [13-17], only one Aurora
A kinase inhibitor (MLN8237) is in a Phase II clinical tri-
als for patients with unrespectable Stage III-IV melanoma
(clinicaltrials.gov). Recently, literature data reported the
promising opportunity to combine the inhibition of
Aurora A kinase with that of BRAF or MEK in BRAF mu-
tated or wild type MM models [13], while no evidence
currently exist testing the combination of Aurora kinases
inhibitors with chemotherapy in melanoma treatment.
In this report, we explored the reliability of targeting
Aurora B kinase which plays a crucial role in cell mitosis
[18]. The Aurora B kinase trough the phosphorylation of
histone H3 and by forming the chromosomal passenger
complex (CPC) together with survivin, INCENP and
borealin, allows the segregation of chromatids at mitosis
and the corrected cytokinesis [19].
Therefore inhibiting Aurora B kinase results in the im-
pairment of cellular mechanisms leading to mitosis and
tumor proliferation. The use of Aurora B kinase inhibi-
tors for therapeutic uses is also suggested from the
observation that the expression and activity of this pro-
tein is increased during melanoma progression [20-22].Several small molecules, inhibitors of Aurora B kinase
have been developed and are currently in early clinical
evaluation for treatment of various tumor pathologies.
They include barasertib, the drug used in our study
[23-25]. Barasertib (AZD1152, kindly provided by
AstraZeneca) is a dihydrogen phosphate prodrug of a
pyrazolo quinazoline Aurora kinase inhibitor [AZD1152]
that is rapidly converted into the active moiety barasertib-
HQPA following parenteral administration; then the ac-
tive metabolite is a highly potent and selective inhibitor
of Aurora B kinase [26]. Currently, barasertib is on-
going in a phase I/II trials for the treatment of patients
with Diffuse Large B-cell Lymphoma and in a phase II/
III trials alone and in combination with low dose of
cytosine arabinoside in acute myeloid leukaemia pa-
tients (SPARK-AML1) (www.clinicaltrials.gov). Here,
we evaluated the anti-tumor effects of barasertib-
HQPA in MM cell models carrying BRAF(V600E) or
BRAF(V600K) mutations and wild type BRAF in order
to evaluate the efficacy of barasertib in cells responding
to anti-BRAF vemurafenib and do not, respectively. We
found that barasertib was very effective in inhibiting
tumor proliferation of both BRAF mutated and wt cells.
Interestingly, as a consequence of the exposure to bara-
sertib we observed that the higher the efficacy of the
drug the higher was the release of lactate, hence sug-
gesting that it could be utilized as a biomarker of re-
sponse to barasertib in MM cells. In addition we
combined barasertib-HQPA with vemurafenib in order
to gain further knowledge on the possibility to over-
come resistance to vemurafenib by targeting Aurora B
kinase. Moreover we combined barasertib-HQPA with
nab-paclitaxel in order to assess the optimal combin-
ation schedule with chemotherapy and provide evi-
dence on an innovative therapeutic approach to be
used for the treatment of melanoma.
Methods
Drugs and chemicals
Barasertib-HQPA was provided by AstraZeneca Pharma-
ceuticals (Macclesfield, U.K.). Stock solutions of Barasertib-
HQPA were prepared at 20 mM in DMSO and stored in
aliquots at –20°C. Further dilutions were made in medium
supplemented with 10% foetal bovine serum, 2 mM glu-
tamine, 50,000 UL−1 penicillin and 80 μM streptomycin.
Cell lines
The Hmel-1, MBA72 cell lines was obtained from bioptic
samples of MM and genotyping for NRAS and BRAF
[27,28]. Hmel-1 showed BRAF mutation in V600K and
MBA72 in V600E, both in heterozygosis. HBL, LND1 cell
lines, both wild type (wt) for BRAF, are a gift of Prof. G.
Ghanem, University of Bruxelles. All cell lines were wt
for NRAS. Cells were cultured in vitro in D-MEM
Porcelli et al. Journal of Translational Medicine  (2015) 13:26 Page 3 of 13supplemented with 10% foetal bovine serum, 100 U/ml
penicillin, 100 μg/ml streptomycin in a humidified incuba-
tor at 37°C with an atmosphere containing 5% CO2.
Cell imaging
Cells were exposed to 30 and 300 nM barasertib-HQPA
for 1-3 days and their shape were analysed by light
inverted microscopy.
Cell proliferation assay
Determination of cell growth inhibition was performed
using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetra-
zoliumbromide (MTT) assay and by cell counting. The
MTT assay for the determination of the concentration
responsible for 50% inhibition of cell growth (IC50) was
performed as described in Porcelli et al. [29]. The IC50
was defined as the drug concentration yielding a fraction
of affected (no surviving) cells = 0.5, compared with un-
treated controls and was calculated utilising CalcuSyn
ver.1.1.4 software (Biosoft, UK).
For cell count determination, cells were exposed to
barasertib-HQPA alone or in combination with vemura-
fenib or nab-paclitaxel, harvested in trypsin and cells
were counted. Barasertib -HQPA was given at 30 and
300 nM, vemurafenib at the IC50 concentration and nab-
paclitaxel at 50 nM which induced after 3 days about
the 50% of cells death. The Combination Index (CI) was
calculated by CompuSyn for Drug Combinations and for
General Dose-Effect Analysis (ComboSyn, Inc. 599 Mill
Run, Paramus, NJ, 07653, USA). CI < 1 means synergism;
CI > 1 means antagonism; CI = 1 means additivity.
Cell cycle analysis
After two wash steps in ice-cold PBS (pH 7.4), cells were
fixed in 4.5 ml of 70% ethanol and stored at -20°C. For
the analysis, the pellet was resuspended in PBS contain-
ing 1 mg/ml RNase, 0.01% NP40 and 50 μg/ml propi-
dium iodide (PI) (Sigma). After an incubation time of 1
hour in ice, cell cycle determinations were performed
using a FACScan flow cytometer (Becton Dickinson),
and data were interpreted using the CellQuest software,
provided by the manufacturer.
Cell apoptosis assay
Apoptosis detection was further investigated by the Cell
Death ELISAPLUS kit (Roche Molecular Biochemicals,
Milan, Italy). The test is based on the detection of
mono- and oligonucleosomes in the cytoplasmic fraction
of cell lysates by biotinylated anti histone-coupled anti-
bodies, and their enrichment in the cytoplasm is calcu-
lated as the absorbance of sample cells/absorbance of
control cells. The enrichment factor was used as a par-
ameter of apoptosis and shown on the Y-axis as mean ±SE. Experiments were performed according to manufac-
turer’s instructions.
Lactate dehydrogenase activity
Cells undergoing necrosis typically exhibit rapid swell-
ing, loss of membrane integrity, and release of lactate
dehydrogenase (LDH). This enzyme activity into the cul-
ture medium was measured as described by Bernt and
Bergmeyer [30] and expressed as percent of maximum
LDH released 3 days after drug(s) exposure [31]. An ali-
quot (100 μl) of culture medium (5×104 cells/1 ml cul-
ture medium) was added to 2 ml of 50 mM Tris–HCl
buffer pH 7.4 in the presence of 0.2 mM NADH. The
assay reaction was started by adding 0.6 mM pyruvate.
Wound healing assay
Confluent monolayer of MM cells were wounded and
treated with barasertib-HQPA (30-300 nM) or left un-
treated (control). The plates were photographed 0, 24 and
48 hours post-wounding. Cell migration was quantified by
counting the wound width after the plates were treated,
utilizing ImageJ® analysis software. Results are given as mi-
gration length and are accounted for by the average per
field ± S.D. of three independent experiments.
Western blot analysis
Protein extracts were obtained by homogenization in
RIPA buffer (0.5 M NaCl, 1% Triton X100, 0.5% NP40, 1%
deoxycolic acid, 3.5 mM SDS, 8.3 mM Tris HCl pH 7.4,
1.6 mM Tris base) and treated with 1 mM phenylmethyl-
sulfonyl fluoride (PMSF). Total proteins were measured
and analyzed as described in [32]. 50 μg were electrophor-
etically separated on 10% acrylamide gel (SDS–PAGE by
Laemli). Signal was detected by chemoluminescence assay
(ECL-Plus, Amersham Life Science, UK). Expression levels
were evaluated by densitometric analysis using Quantity
One software (Biorad, Hercules, CA) and β-actin expres-
sion levels were used to normalize the sample values.
Antibodies
All monoclonal antibodies utilised were provided by Cell
Signalling-USA and Sigma-Aldrich, St. Louis, MO-USA.
A mouse-HRP and a rabbit-HRP (Amersham Pharmacia
Biotech, Upsala Sweden) were used as secondary antibody.
Fluorescence immunocytochemistry
Cells were seeded onto coverslips. After overnight incuba-
tion, they were fixed in 3.7% paraformaldehyde, washed
and permeabilized with 0.1% Triton X-100. Nuclei were
counterstained with 0.5 mg/ml 4′,6-diamidino-2-pheny-
lindole (DAPI). The images were captured using a fluores-
cence microscope (Olympus BX40), equipped with X20
objective with a SenSys 1401E-Photometrics charge-
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laserline and DAPI using the 568 laserline.
Extracellular lactate level
The amount of lactate in the cell medium was estimated
following spectrophotometrically NADH oxidation at
340 nm as described in Pacelli et al. [33].
Statistical analysis
All in vitro experiments were performed in triplicate,
and results have been expressed as the mean ± standard
deviation (SD), unless otherwise indicated. Statistical dif-
ferences of in vitro and in vivo data were assessed by
ANOVA, followed by the Student-Newman–Keuls test.
P-values lower than 0.05 were considered significant.
Statistical analyses were performed using the GraphPad
Prism software package version 5.0 (GraphPad Software
Inc., San Diego, CA, USA).
Results
Characterization of vemurafenib sensitivity in function of
BRAF status
Sensitivity to vemurafenib was assessed in a panel of 4
cell lines: LND1 and HBL cells which have BRAF wild
type (w.t.) and MBA72 and Hmel-1 cells carrying mu-
tations V600E and V600K in BRAF, both known to be
responsible for high responsiveness to vemurafenib in
patients at least at the beginning of the therapy
[27,28,1,34]. As expected, cells with mutated-BRAF were
sensitive to vemurafenib showing an IC50 ranging between
3 and 5 μM; the IC50 value increased of 10-times in the
BRAF w.t. cells (see Additional file 1: Figure S1(A) and
Table 1). In order to mimic the induction of resistance to
vemurafenib observed in MM patients treated with this
drug, all the cells carrying BRAF mutations were chronic-
ally (21 days) treated with vemurafenib. After 21 days of
exposure, the IC50 of still proliferating cells increased of
about 10 and 5 times in MBA72 and Hmel-1, respectively
(Table 1). These newly established cell lines were named
MBA72R and Hmel-1R.Table 1 Vemurafenib and barasertib activity evaluation in
living cell lines
Cell
line
BRAF
status
3 days-vemurafenib 3 days-barasertib-HQPA
IC50 (μM) IC50 (nM)
MBA72 V600E 3.2 ± 0.6 305 ± 4
Hmel-1 V600K 5.5 ± 0.4 311 ± 6
LND1 wild type 32.2 ± 1.1 307 ± 7
HBL wild type 37.3 ± 0.9 315 ± 11
MBA72R V600E 33.5 ± 0.5 367 ± 10
Hmel-1R V600K 25.8 ± 0.5 184 ± 8Determinants of induced-resistance to vemurafenib in
MBA72R and Hmel-1R
The onset of resistance to vemurafenib has been exten-
sively studied and various cellular determinants respon-
sible for this have been identified [5,35].
A preliminary screening of the biomarkers responsible
for drug resistance in the two cell lines, and MBA72R
and Hmel-1R, was conducted focusing on the involve-
ment of i) the determinants of cell cycle progression by
analysis of its perturbation, ii) Akt, Erk1/2 and p-38, ac-
tivated as a consequence of the induction of resistance
to vemurafenib, and finally it was also considered the
possible involvement of MITF.
In Figure 1A, histograms of cell cycle progression in
the pairs of cell lines (MBA72 vs MBA72R and Hmel-1
vs Hmel-1R) are reported in which no evident changes
in cell cycle progression are present suggesting the non-
involvement of cell cycle determinants as responsible for
vemurafenib-resistance. In Figure 1B, the western blot-
ting characterization of pAkt/Akt, p-p38/p38 MAPK and
pErk1/2/Erk1/2 are reported; Akt did not show any stat-
istical variation from baseline level while Erk1/2 and p38
MAPK were activated only in Hmel-1R with an increase
of pErk1/2 and p-p38 MAPK of 350 and 750% as respect
the naïve cells. In Figure 1C, MITF determination by
flow cytometry is showed with an increase of this tran-
scription factor only in MBA72R (3.58 folds higher than
in MITF negative-naïve cells) and the expression level is
similar to that in HBL cells (about 2.19 folds higher that
the negative cells), intrinsically resistant to vemurafenib.
Thus, our results demonstrated that the chronic expos-
ure to vemurafenib induced a decrease of drug sensitiv-
ity in function of the activation of Erk1/2 and p38
MAPK and the increase of MITF expression level in
Hmel-1R and MBA72R, respectively.Barasertib-HQPA modifies cellular morphology and
inhibits cell growth in function of drug concentration
Barasertib-HQPA increased cell size and consequently,
only a direct counting of cells after drug(s) treatment
provides a correct analysis of its cytotoxicity [26].
All cell lines were incubated in a range from 3 nM to 3
μM barasertib-HQPA for 3 days and the cell count showed
that this inhibitor reduced cell proliferation in function of
concentration (Additional file 1: Figure S1 and Table 1).
The IC50 values are about 300 nM in all cells with the ex-
ception of Hmel-1R which resulted a little more sensitive as
respect to the naïve cells. Prolonged drug exposure (6 days)
was more effective in BRAF wt cells compared to BRAF-
mutated ones and the exposure to barasertib-HQPA for 3
days followed by 3 days-drug wash out induced a marked
recover of cell growth only in MBA72 (Additional file 1:
Figure S1).
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Figure 1 Determinants of resistance to vemurafenib. A. Cell cycle progression of the two pair of cells, MBA72/ MBA72R and Hmel-1/Hmel-1R,
were determined as described in M&M section. B. p-Erk1/2, Erk1/2, p-Akt, Akt, p-p38 MAPK and p38 MAPK were analysed in cells by western
blotting and protein amount determined by densitometry analysis. Histograms are means of at least three different experiments. *p < 0.05 vs
untreated cells. C. The expression level of MITF was determined by FCM in MBA72, MBA72R and HBL as respect to the isotype.
Porcelli et al. Journal of Translational Medicine  (2015) 13:26 Page 5 of 13All following experiments were carried out with barasertib-
HQPA at 30 and 300 nM, the highest concentration is com-
parable to the IC50s and the lowest could provide evidences
on the efficacy of the drug at subtoxic concentration.
In Figure 2A cellular morphology after treatment with
the Aurora B kinase inhibitor in HBL1 cells is reported
and is representative of the marked phenotypical alter-
ations obtained treating melanoma cells with this drug;
the incubation with 300 nM barasertib-HQPA (for 3
days) caused the formation of giant cells with irregular
shapes, suggesting a failure of cytokinesis [36].
Barasertib-HQPA perturbs cell cycle progression
The marked reduction of cell growth may be justified by
a strong perturbation of cell cycle progression. Thishypothesis has been investigated in all melanoma cell lines
in function of drug concentration and exposure time. In
Figure 2B, only results obtained in HBL, Hmel-1 and in
the pair MBA72/MBA72R are reported and the cell cycle
progression of HBL and MBA72R are similar to those ob-
tained for LND1 and Hmel-1R, respectively.
In BRAF wt cells, 1 day exposure to 30-300 nM
barasertib-HQPA induced cell cycle arrest in mitosis with
a strong accumulation of 4N cell population. After 3 days
of treatment cells undergone an additional round of DNA
duplication while failing cytokinesis, then 8N cells popu-
lation started accumulating in a range from 8% in BRAF
mutated to 43% in BRAF wt cells (inserts in Figure 2B).
The behavior was similar, though less marked in BRAF-
mutated cells, both in cell lines sensitive and resistant to
AB
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Figure 2 Morphological changes and cell cycle perturbation by barasertib-HQPA exposure. A. Increase in HBL cell size induced by
barasertib-HQPA exposure at 300 nM by light inverted microscopy. B. Cells were incubated, for one and three days, with barasertib-HQPA (30 and
300 nM) and the cell cycle was analysed by flow cytometry analysis as described in M & M section. Experiments were performed in triplicate
obtaining similar results and histograms are representative for all of them. Results of 3 days-exposure are reported in the inserts.
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tion of polyploid cells depending on drug concentration
and time exposure.
Barasertib-HQPA induces mitotic catastrophe
Barasertib-HQPA induced the accumulation of 4N and
8N cell population thus, the hypothesis that this drug
may be an inducer of mitotic catastrophe was investi-
gated. Mitotic catastrophe is a mechanism of cell death
characterized by the occurrence of aberrant mitosis with
the formation of large cells that contain multiple nuclei,
which are morphologically distinguishable from apop-
totic cells. Nuclear morphology after drug treatment was
determined by DAPI staining and, as shown in Figure 3,
cells exhibited pronounced changes in nuclear morph-
ology and chromatin organization with visible multinu-
cleated cells. The phenomenon increased in function of
drug concentration but not of exposure timing and is
irrespective of BRAF mutational status. This evidence,
together with the appearance of giant cells with an un-
usual shape typical of cells which failed cytokinesis, sug-
gests that the mitotic catastrophe may be a mediator of
cell death activated by barasertib-HQPA in such MM
models.
Barasertib-HQPA induced apoptosis and necrosis
In a previous study, we demonstrated that the inhibition of
Aurora B kinase activity by treatment with barasertib-
HQPA induces apoptosis [26]. Here, the ability of this drug
to induce cell death through various mechanisms was in-
vestigated. In addition to mitotic catastrophe, suggested in
the previous paragraph, the induction of apoptosis andFigure 3 Modification of nuclear morphology following exposure to b
and 300 nM barasertib-HQPA and after three and six days, polynucleate cenecrosis was evaluated by the DNA laddering and the
LDH activity assay, respectively [37].
In Figure 4A, apoptosis induction by barasertib-HQPA or
vemurafenib is reported and the first is responsible for pro-
grammed cell death increasing in function of drug concen-
tration; conversely, vemurafenib induced apoptosis only in
BRAF mutated cells as previously showed. In BRAF wt cells,
vemurafenib did not activate this kind of death and the
mechanism responsible for this lack of activity will be further
investigated. Necrosis was determined by the analysis of
LDH activity [30] and our data suggest that, in the presence
of 30 and 300 nM barasertib-HQPA as well as of vemura-
fenib, cell death occurred via apoptosis and via necrosis
except in HBL (Figure 4B). This increased LDH activity was
depended on drug concentration. To explain the different
behavior of HBL compared to LND-1 cells, the hypothesis
that will be verified in the next future is that a low intracellu-
lar concentration of ATP might be responsible for the switch
from apoptosis to necrosis, as suggested by Lemasters [38].
Barasertib-HQPA activity was independent from survival
and proliferation pathway
To explore the cellular pathways involved in determining
barasertib-HQPA activity, the expression level of Erk1/2,
Akt and p-38 in their phosphorylated forms as well as total
ones were investigated by Western Blotting (Additional
file 2: Figure S2). Results evidenced the absence of drug
ability to modulate the basal forms of all proteins (not
shown). In agreement with the involvement of Erk1/2 with
the establishment of drug resistance [5], this protein was
found activated after only 3 day-vemurafenib exposure in
BRAF wt cells, which are resistant to vemurafenib perhapsarasertib-HQPA. BRAF-mutated melanoma cells were exposed to 30
lls were evidenced by ICC (blue: DAPI).
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Figure 4 Effect of barasertib-HQPA and vemurafenib on apoptosis and necrosis. Melanoma cells were treated with 30 and 300 nM
barasertib-HQPA (Bar) and vemurafenib (Vem) at IC50s. (A) Apoptosis was determined by Cell Death ELISA assay and (B) Necrosis by LDH activity
determination and expressed as percentage respect to the untreated cells. *p < 0.05 vs untreated cells.
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ation of Erk1/2, but not in mutated cells, intrinsically sensi-
tive to the BRAF inhibitor.
Barasertib-HQPA inhibits cell migration
The anti-invasive effects of barasertib-HQPA were investi-
gated on cellular motility by wound healing assay. A quite
complete wound healing was evident when untreated cellsFigure 5 Barasertib-HQPA ability to modulate cellular motility. Wound
barasertib-HQPA. Cell migration was quantified with ImageJ® analysis softw
concentration. *p < 0.05 vs untreated cells.were incubated at 37°C for 48 h conversely, monolayers
treated with barasertib-HQPA, at 30 and 300 nM, showed
clear wound width after 48 h in all cellular panels. Images
and the quantified average gaps obtained in BRAF wt and
mutated cells are reported in Additional file 3: Figure S3
and Figure 5, respectively. These results confirmed the
ability of this compound to inhibit cell migration in a
concentration-dependent way in this MM model.healing assay was performed at 24-48 h with 30 and 300 nM
are and results are expressed as percentage of average gab vs drug
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The lactate was assayed as described in Methods and in
all cells; the 3 days-exposure to barasertib-HQPA in-
duced a significant concentration-dependent increase of
the extracellular lactate levels mainly in BRAF wt cells
conversely, vemurafenib reduced it only in the same
model. (Figure 6A). In HBL cells (BRAF wt), the release
of lactate in the medium after exposure to barasertib-
HQPA was made using a wider range of concentrations
and increasing the time of exposure to 6 days. The re-
sults showed a progressive increased release of lactate in
function of the concentration and exposure time in HBL
cells (Figure 6B).
Barasertib-HQPA plus vemurafenib, a promising
opportunity?
The first combined approach explored in this study was
the administration of barasertib-HQPA plus vemurafenib
with the aim to restore the sensitivity to vemurafenib.
Unfortunately, after the simultaneous exposure to
barasertib-HQPA plus vemurafenib in MBA72R and Hmel-
1R the inhibition of cell proliferation remained the same in-
duced by barasertib alone (Additional file 4: Figure S4 A).
The effectiveness of three schedules, i.e. barasertib-
HQPA together, before and after, was investigated in theA
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Figure 6 Effect of barasertib-HQPA and vemurafenib on lactate produ
medium of cells exposed to either vehicle or barasertib (Bar) or vemurafen
calculated with Student’s t test; *p < 0.05 vs untreated cells. In B, the curve
concentration (3, 30, 300 nM) and after 6 days of drug exposure.responsive cell lines MBA72 and Hmel-1 which showed a
different response. In MBA72 cells, harboring the muta-
tion BRAF(V600E), the combination of the two drugs in
all schedules was not effective, suggesting an antagonism
between the two drugs. In Hmel-1, harboring the muta-
tion BRAF(V600K), the sequential schedules were more
effective than each drug alone conversely, the effectiveness
of the combination did not increase when the two drugs
were given simultaneously (Additional file 4: Figure S4 B).
Thus, these data suggest to further explore whether the
mutation BRAF V600K may be responsible for the in-
creased effectiveness of the two drugs in combination.
Barasertib-HQPA plus nab-paclitaxel: how relevant is the
schedule?
The promising approach to combine new biological agent
with conventional chemotherapeutics and the low number
of chemotherapeutics utilised in this pathology suggested
the combined administration of barasertib-HQPA plus
nab-paclitaxel, a taxane derivative. The scientific rationale
relays on the selective effect of each drug on mitotic
machinery; paclitaxel arrests cells division by stabilizing
microtubule polymers thereby disrupting the cellular
machinery required for mitotic spindle assembly and ba-
rasertib inhibits Aurora B kinase, which forms the0 30 300 30 0 30 300 30
) Bar (nM)  Vem (μM) Bar (nM)  Vem (μM)
*
                     LND1                         HBL
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ction. In A, extracellular lactate level was measured in the growth
ib (Vem) after 3 days. Data are means ± SEM and significance was
of the release of lactate are shown in function of barasertib-HQPA
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correct cytokinesis.
The analysis of barasertib-HQPA and nab-paclitaxel in
combination was performed utilising the first drug at four
different concentrations (3, 30, 300 nM and 3 μM) and
nab-paclitaxel at the fix dose of 50 nM. Three administra-
tion schedules were tested: simultaneous, barasertib-
HQPA before and barasertib-HQPA after. Promising are
all schedules utilized, in fact, either in BRAF wt cells and
in mutated ones, the drugs combination induced a reduc-
tion of cell proliferation showing a synergic interaction
(CI < 1) in quite all samples (Figure 7) suggesting the exist-
ence of a close interconnection between the pathways ofC
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barasertib-HQPA (bar) plus 50nM nab-paclitaxel (n-pac) given in three sche
3 days-nab-paclitaxel. A. The survival of cells is reported as dose/effect plot
CompuSyn software is summarized in the table.action of the drugs. Indeed, the analysis of the nuclear
morphology carried out on HBL cells, evidenced nuclear
dysfunction which is consequent to mitotic abnormalities
caused by each drug. Barasertib-HQPA induced the for-
mation of big nuclei as a consequence of polyploidy and
nuclear budding which is a biomarker of chromosomal in-
stability; nab-paclitaxel resulted in the formation of mi-
totic aggregates of condensed chromosomes, conceivably
due to the blockage of microtubule-dependent processes
required for metaphase/anaphase transition. The combin-
ation of the two drugs resulted in a lethal effect, as all the
nuclei in the observed specimens display necrotic and
apoptotic like features (Additional file 5: Figure S5).C
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s. B. The quantification of the CIs of each drugs combination by
Porcelli et al. Journal of Translational Medicine  (2015) 13:26 Page 11 of 13Discussion
Aurora B kinase is increasingly overexpressed during
melanoma progression with a concomitant enhancement
of its activity, hence suggesting that it is a promising cel-
lular target for personalized anticancer therapy in this
disease [20-22]. Recently, Bonnet and coauthors pro-
vided evidences on the possibility to utilize barasertib,
an Aurora B kinase inhibitor, as a new therapeutic strat-
egy in both wild-type BRAF and vemurafenib-resistant
BRAFV600E melanoma, stressing the idea that Aurora B
kinase is a potential target in the therapy of MM [18].
Here, we provide preclinical evidence on the utilization
of barasertib-HQPA in MM cell lines, including both
BRAF wt and mutated cells and also two vemurafenib in-
duced resistant cell lines. In addition we demonstrated
that the inhibition of Aurora B kinase could improve the
response to vemurafenib and to nab-paclitaxel, the latter
recently included in clinical trials for treatment of MM.
All characterization was performed by taking into ac-
count the molecular characteristics of cells and results
obtained suggested the utilization of barasertib in mono
and multi-therapy in BRAF wt and mutated population.
The in vitro panel was characterized for vemurafenib
sensitivity, confirming the effectiveness of this drug in
the BRAF mutated cells conversely, it acted at ten-folds
higher doses in the BRAF wt and in those which became
resistant after chronic exposure to subtoxic doses of
vemurafenib. A preliminary characterization of the cellu-
lar determinants responsible for the acquired-resistance
to vemurafenib evidenced that the reactivation of Mek/
Erk1/2 and p38 MAPK pathways might be involved in
the establishment of resistance to the drug in Hmel-1,
while the amplification of MITF was found in MBA72
cells after continuous exposure to vemurafenib. All these
alterations have been already demonstrated to be directly
related with the onset of the resistance to BRAF inhibi-
tors [5,35,39,40].
All MM cells incubated with the Aurora B kinase in-
hibitor showed marked modification of the cellular
morphology and a strong reduction of cells proliferation.
Extending drug exposure to 6 days evidenced a differ-
ence between cells; BRAF wt cells were more sensitive
than BRAF-mutated ones, both sensitive to vemurafenib
and their resistant counterparts.
The importance of the identification of a predictive
factor for a drug effectiveness is ubiquitously accepted,
the scanty and contradictory evidences on biomarkers
predicting the efficacy of Aurora kinase inhibitors re-
ported in literature focused initially on CHFR, a mitotic
checkpoint protein and p53, the inactivation of which
leads to increased sensitivity to this class of drugs
[41-43]. Recently, new technologies which highlighted
genomic aberrations (point mutations, amplifications
and rearrangements) have added new hypothesis. Simonand Roychowdhury suggested the amplification of the
Aurora A Kinase (AURKA) in prostate and breast cancer
[44]. According to the evidence that cells with high
endoreduplication showed increased glycolytic metabol-
ism with consequent increase of lactate release [45], in
our models, barasertib-HQPA induced a marked in-
crease of this metabolite in the medium in function of
time and drug concentration. As the BRAF wt cells
which released the highest level of lactate were the most
sensitive to the drug, this suggested that the lactate re-
lease might predict drug effectiveness. The evidence that
in BRAF mutated cells vemurafenib did not affect lactate
levels while it was significantly reduced in BRAF wt cells
is in disagreement with data reported in the literature in
which a strict correlation between vemurafenib-induced
p-Erk1/2 inhibition and reduction of glycolisis is hypoth-
esized [46]. This discrepancy may lie in the different
ability of the drug to affect pErk1/2 level with a strong
increase or an absence of effect, in BRAF wt and mu-
tated MM cells, respectively. Further investigations are
warranted to highlight the relation between vemurafenib
and glycolysis in such models.
The effectiveness of barasertib-HQPA in inhibiting cell
proliferation was irrespective of BRAF mutation status.
This suggested to investigate combination schedules of
barasertib-HQPA with vemurafenib in order to restore
and/or increase the sensitivity to vemurafenib in no longer
sensitive cells. Our results showed that the Aurora B kin-
ase inhibitor did not restore the sensitivity to vemurafenib
in both resistant cells lines and that the two drugs were
antagonist in cells harboring the BRAF(V600E) mutation.
This result could be explained by the decrease of Aurora
B kinase after vemurafenib exposure reported by other au-
thors who suggested for such kinase a role as predictor
factor for the response to BRAF inhibitors [18,20].
Thus, our data suggest that barasertib could be a prom-
ising approach for treatment of MM patients with BRAF
wt, for whom no effective therapy are actually available,
and for BRAF mutated MM patients as an alternative to
vemurafenib. Moreover, the combination of barasertib-
HQPA with vemurafenib resulted in a slight gain of effect-
iveness, irrespective of the schedule utilized, when the cell
model harbors the mutation BRAF(V600K). This evidence,
if supported by further investigation already in progress in
our lab, could allow a better selection of MM population
to treat with this innovative multidrug approach.
The investigation of the mechanism of action of
barasertib-HQPA in our cell panel evidenced a marked
G2/M phase cell accumulation associated with endore-
duplication, increased DNA content, consequent death
of cells, which occurred through mitotic catastrophe,
apoptosis and necrosis induction. Moreover, barasertib-
HQPA inhibited cell migration, showing to affect the in-
vasive behavior of metastatic melanoma. Our results are
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duce cell death by the activation of different mechanisms
such as necrosis, apoptosis, mitotic catastrophe, senes-
cence [26,47]. Further analysis will be focused on the
possibility that senescence may be involved in determin-
ing the effectiveness of barasertib and Raf kinase Inihibi-
tory Protein (RKIP) may be responsible for the crosstalk
between Aurora B kinase pathway and Raf/MEK/Erk sig-
naling in cells, in which the last is affected by the estab-
lishment of resistance to vemurafenib, and on the study
of the crosstalk between the different pathways respon-
sible for each type of cell death, with the aim of identify-
ing how to switch from one to the other and optimize
the clinical use of this drug [18,48]. The other explored
therapeutic strategy was the combination of barasertib-
HQPA plus nab-paclitaxel.
All the combinations with barasertib-HQPA and nab-
paclitaxel resulted much more effective than each drug
alone in inhibiting cell proliferation. This demonstrated
that the combination schedule utilized is not relevant for
treatment efficacy, most likely because each drug effect
was anyhow synergic and resulted in an override of the
mitotic arrest, with a more severely affected alignment
of chromosomes and more aberrant nuclei with con-
comitant cell death induction.
Conclusion
The evidence reported here further establishes Aurora B
kinase as a therapeutic target in the treatment of both
BRAF wild type and V600 mutated melanoma either
vemurafenib responsive and no longer responsive melan-
oma. Targeting Aurora B kinase potentially has a dual anti-
tumor role, by directly inhibiting migration and growth of
cells and as enhancer of vemurafenib efficacy in BRAF
(V600K) melanoma and of nab-paclitaxel based chemother-
apy in BRAF wild type and mutated melanoma. In addition,
through the combination study of barasertib with nab-
paclitaxel we provide a proof of concept of the reliability of
such combination suggesting administration schedules that
properly validated in vivo and in rationally designed clinical
trials might be a new efficient approach to treat melanoma.
Additional files
Additional file 1: Figure S1. Vemurafenib and barasertib-HQPA
activity in melanoma cell panel. A. Melanoma cells were incubated with
vemurafenib, ranging between 0.1 and 100 μM and the survival of cells
was determined using MTT assay. The results are showed as dose/cell
growth inhibition plots of the mean of three different experiments, evidencing
that mutated cells are more sensitive to the drug. B. Melanoma cells
were incubated with Barasertib-HQPA, ranging between 3 nM and 3 μM
and for increasing time. The survival of cells was determined using direct
cell count. The results are showed as drug cell proliferation inhibition/
dose plots of the mean of three different experiments, evidencing that
BRAF wt cells are more sensitive to the drug than the BRAF mutated
ones.Additional file 2: Figure S2. Effect of barasertib-HQPA and vemurafenib on
cell transduction pathways. Both BRAF-mutated and wt melanoma cells were
incubated with barasertib-HQPA (Bar) and vemurafenib (Vem) for 3 days. The
protein extracts from all samples were analysed by western blot utilising the
β-actin to normalize the values and are quantified as phosphorylated form as
respect the total one. A. Bands of p-Erk1/2 expression level from all samples
are reported together with the quantification. Histograms are means of at least
three different experiments. *p < 0.05 vs untreated cells. *p < 0.05 vs untreated
cells.
Additional file 3: Figure S3. Barasertib-HQPA ability to modulate
cellular motility. Wound healing assay was performed at 24-48 h with 30
and 300 nM barasertib-HQPA.
Additional file 4: Figure S4. Barasertib-HQPA plus vemurafenib in
mutated melanoma cells. A. MBA72R and Hmel-1R were incubated with
300 nM barasertib-HQPA (Bar) and/or Vemurafenib (Vem: at 3.2 and 5.5
μM in MBA72R and Hmel-1R, respectively) for 3 days. The proliferating
cells were determined using the direct cell count. Histograms are means
of at least three different experiments. B. MBA72 and Hmel-1 cells were
incubated with barasertib-HQPA plus vemurafenib given in three schedules,
simultaneous (3 days) and 3 days-barasertib-HQPA (3, 30, 300, 3000 nM)
before or after 3daysvemurafenib, and the survival of cells was determined
using the direct cell count.
Additional file 5: Figure S5. Barasertib-HQPA plus nab-paclitaxel in
melanoma cell panel. HBL cells exposed to 300 nM barasertib-HQPA and
50 nM nab-paclitaxel, alone or in combination, and polynucleate cells
were evidenced by ICC (blue: DAPI).
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